Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186433 · ClinicalTrials.gov registry record
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 49
- Enrollment target
NCT00186433: Completed study, sponsored by Stanford University.
NCT00186433 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186433 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas. 3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2001-11 |
| Est. Completion | 2013-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186433
The ClinicalTrials.gov registry entry for NCT00186433 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00186433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186433 about?
NCT00186433 is a clinical study titled "A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations". 1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors b...
What is the current status of trial NCT00186433?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2001-11. Estimated completion is 2013-06.
Who is sponsoring clinical trial NCT00186433?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.